Psychedelic Therapy in Switzerland: BAG Regulations and Access

Switzerland's Unique Position

Switzerland occupies a distinctive place in the global psychedelic therapy landscape. Through the Bundesamt fuer Gesundheit (BAG) — the Federal Office of Public Health — qualified psychiatrists can obtain exceptional permits to use substances like LSD and psilocybin in therapeutic settings.

This framework predates the current psychedelic renaissance. Switzerland was one of the first countries to allow compassionate use of psychedelics, with permits issued as early as the 1990s under psychiatrist Peter Gasser.

The BAG Exceptional Permit System

How It Works

The BAG's compassionate use pathway allows licensed psychiatrists to apply for permits on a patient-by-patient basis:

Clinical justification — The psychiatrist must demonstrate that conventional treatments have been inadequate

Patient assessment — Comprehensive psychiatric evaluation including screening for contraindications

Application submission — Detailed treatment plan submitted to the BAG

Permit approval — BAG reviews and may grant an exceptional use permit

Supervised treatment — Therapy conducted under strict medical protocols

Outcome reporting — Psychiatrists must report treatment outcomes to the BAG

Substances Available

Under exceptional permits, the following substances have been approved for therapeutic use:

LSD (lysergic acid diethylamide) — Most commonly approved substance

Psilocybin — Increasingly requested for depression and end-of-life anxiety

MDMA — For PTSD cases, though less commonly approved

DMT/Ayahuasca — Rare but documented cases

Growth in Applications

The number of BAG permit applications has increased significantly:

2018: Approximately 30 active permits

2020: Over 60 active permits

2022: Over 100 active permits

2024-2025: Continued growth as awareness spreads

This growth reflects both increasing clinical evidence and growing patient demand. Explore related research on PsiHub.

Key Swiss Research Institutions

Switzerland hosts several leading psychedelic research centers:

University Hospital Basel — Led by Prof. Matthias Liechti, conducting clinical trials with LSD, psilocybin, and MDMA

University of Zurich — Neuroimaging studies on psychedelic mechanisms

Swiss Institute for Psychedelic Research — Coordinating clinical research efforts

Challenges and Considerations

Despite Switzerland's progressive stance, challenges remain:

Cost — Psychedelic-assisted therapy sessions are lengthy (8+ hours) and expensive

Insurance coverage — Not consistently covered by health insurance

Training — Limited number of psychiatrists with appropriate training

Quality control — Ensuring consistent substance quality across treatments

Follow-up — Standardized integration protocols are still evolving

Comparison with Other Countries

Switzerland's approach differs from other jurisdictions:

More flexible than the US FDA pathway, which requires full clinical trial data

More restrictive than Oregon's direct-to-consumer model

Similar to Australia's authorized prescriber framework

A model for other European countries considering regulatory pathways

Learn more about global regulatory developments on PsiHub.

References

Gasser, P. et al. (2014). Safety and efficacy of LSD-assisted psychotherapy. Journal of Nervous and Mental Disease.

Liechti, M.E. (2017). Modern clinical research on LSD. Neuropsychopharmacology.

Regulatory updates tracked on PsiHub